AevisBio entered into a CRADA with the NIA, part of the NIH

관리자 │ 2023-01-17



AevisBio, Inc., a company specializing in developing therapeutics for anti-inflammatory diseases has entered into a cooperative research and development agreement with the National Institute on Aging (NIA), an institute of the National Institutes of Health (NIH), U.S. Department of Health and Human Services since August 2019. This collaboration is for the development of NIH-developed anti-inflammatory drug candidates for the management of acute and chronic neurological disorders. 

Previous Post Korean Government grant (TIPS) awarded
Next Post South Korea's Most Promising Tech Startups Pitch in the U.S. to Top Investors